Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Cholesterol emboli syndrome risk factors

Introduction

Overview

Overview

The most potent risk factor in the development of cholesterol emboli syndrome is atherosclerosis. Other risk factors include cardiovascular interventions such as angiography and cardiovascular surgery, aortic aneurysm, diabetes mellitus, hypertension, dyslipidemia, smoking, aging, male sex, anticoagulants such as warfarin, thrombolytic therapy and higher serum CRP levels.

Risk Factors

Risk Factors

References

References

  1. ↑ 1.0 1.1 Ozkok, Abdullah (2019). “

    Cholesterol-embolization syndrome: current perspectives

    “. Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048.
  2. ↑ Saklayen, Mohammad G.; Gupta, Satyendra; Suryaprasad, Agaram; Azmeh, Wayel; Saklayen, Mohammad G. (2016). “Incidence of Atheroembolic Renal Failure After Coronary Angiography”. Angiology. 48 (7): 609–613. doi:10.1177/000331979704800707. ISSN 0003-3197.
  3. ↑ Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). “The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study”. Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
  4. ↑ Hyman, Bradley T.; Landas, Steve K.; Ashman, Robert F.; Schelper, Robert L.; Robinson, Robert A. (1987). “Warfarin-related purple toes syndrome and cholesterol microembolization”. The American Journal of Medicine. 82 (6): 1233–1237. doi:10.1016/0002-9343(87)90231-2. ISSN 0002-9343.
  5. ↑ Varis, J.; Kuusniemi, K.; Jarvelainen, H. (2010). “Cholesterol microembolization syndrome: a complication of anticoagulant therapy”. Canadian Medical Association Journal. 182 (9): 931–933. doi:10.1503/cmaj.090919. ISSN 0820-3946.
  6. ↑ Hitti, Wassim A; Wali, Ravinder K; Weiman, Edward J; Drachenberg, Cinthia; Briglia, Andrew (2008). “Cholesterol Embolization Syndrome Induced by Thrombolytic Therapy”. American Journal of Cardiovascular Drugs. 8 (1): 27–34. doi:10.2165/00129784-200808010-00004. ISSN 1175-3277.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]